| 摘要: |
| 目的本文主要对贝伐单抗在结直肠癌治疗中的安全性进行研究,以期为临床应用提供一定的指导。方法回顾性分析使用贝伐单抗治疗的72例晚期结直肠癌病例。统计贝伐单抗不良反应发生率,通过单变量和多变量分析以确定贝伐单抗不良反应的潜在危险因素。结果共有72例患者可进行安全性评价。最常见的药物不良反应是高血压(12.5%),出血(12.5%)和蛋白尿(8.3%)。严重药物不良反应的发生率较低:出血的发生率为1.4%,静脉血栓栓塞事件发生率为1.4%,胃肠穿孔发生率为1.4%。通过多变量分析确定出了药物各种不良反应的高危因素。结论贝伐单抗严重不良事件发生率较低,患有晚期或转移性结直肠癌的患者应用贝伐单抗安全性较好,患者的耐受性良好。 |
| 关键词: 晚期结直肠癌 贝伐单抗 安全性 |
| DOI： |
| 分类号: |
| 基金项目:北京市医院管理局“青苗”计划专项经费资助(编号:QML20170102);北京友谊医院院启动基金(编号:yyqdkt 2015-10);北京市自然科学基金资助(编号:7184200) |
|
| Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer |
|
Zhao Lei;Wang Jing;Che Juanjuan
|
|
Cancer Center,Beijing Friendship Hospital,Affiliated to Capital Medical University
|
| Abstract: |
| Objective To study the safety of bevacizumab in the treatment of colorectal cancer,in order to provide some guidance for the clinical application.Methods A retrospective analysis of 72 patients with advanced colorectal cancer who were admitted to our hospital and treated with bevacizumab was conducteol.Adverse reactions and incidence of bevacizumab were collected.A single variable and multivariate analysis was used to determine the potential risk factors for the adverse reactions of bevacizumab.Results A total of 72 patients were evaluable for safety. The most common adverse drug reactions were hypertension( 12. 5%),hemorrhage( 12. 5%),and proteinuria( 8. 3%).The incidence of serious adverse drug reactions was low : the incidence of bleeding was 1. 4 %,the incidence of venous thromboembolism was 1. 4 %,and the incidence of gastrointestinal perforation was1. 4 %.The high risk factors of adverse drug reactions were identified by multivariate analysis.Conclusion Bevacizumab has a low incidence of serious adverse events.Patients with advanced or metastatic colorectal cancer have better safety and better tolerance to bevacizumab |
| Key words: advancedcolorectalcancer bevacizumab safety |
